Corteva (NYSE:CTVA – Get Free Report) had its price objective raised by analysts at Deutsche Bank Aktiengesellschaft from $90.00 to $100.00 in a report released on Monday,MarketScreener reports. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 22.17% from the company’s current price.
A number of other research firms have also recently commented on CTVA. Berenberg Bank lifted their target price on shares of Corteva from $68.00 to $78.00 and gave the stock a “hold” rating in a research note on Thursday, March 26th. Citigroup upped their price target on shares of Corteva from $83.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Royal Bank Of Canada lifted their price objective on shares of Corteva from $95.00 to $97.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Argus boosted their price objective on shares of Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, Wells Fargo & Company upped their target price on Corteva from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, April 21st. Thirteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Corteva presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.52.
Read Our Latest Research Report on Corteva
Corteva Stock Down 1.2%
Corteva (NYSE:CTVA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32. The firm had revenue of $4.91 billion for the quarter, compared to the consensus estimate of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The company’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $1.13 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, research analysts forecast that Corteva will post 3.67 EPS for the current fiscal year.
Insider Activity
In other Corteva news, insider Brian Titus sold 8,311 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total transaction of $636,207.05. Following the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.15% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Corteva
Hedge funds have recently made changes to their positions in the company. Harris Associates L P lifted its stake in shares of Corteva by 168.1% in the fourth quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock worth $1,141,268,000 after buying an additional 10,675,052 shares in the last quarter. Norges Bank purchased a new stake in Corteva during the 4th quarter valued at about $504,001,000. Northwestern Mutual Wealth Management Co. grew its stake in Corteva by 6,527.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,148,212 shares of the company’s stock valued at $211,025,000 after acquiring an additional 3,100,709 shares in the last quarter. Perpetual Ltd raised its holdings in Corteva by 78,688.5% in the 4th quarter. Perpetual Ltd now owns 2,615,779 shares of the company’s stock valued at $175,336,000 after acquiring an additional 2,612,459 shares during the last quarter. Finally, Amundi lifted its stake in Corteva by 125.3% in the 3rd quarter. Amundi now owns 3,415,554 shares of the company’s stock worth $219,620,000 after purchasing an additional 1,899,248 shares in the last quarter. Institutional investors and hedge funds own 81.54% of the company’s stock.
About Corteva
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
Featured Articles
- Five stocks we like better than Corteva
- MP Materials Is Quietly Building a Rare Earth Powerhouse
- AI Demand Fuels Strong Q1 Earnings for Constellation Energy
- Sony’s $4 Billion Bet on Rock & Roll Royalties
- Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.
